

APC/Cyanine7 Streptavidin

Catalog# / Size	405208 / 100 µg
Regulatory Status	RUO
Description	Streptavidin binds to biotin with high affinity. Streptavidin-APC/Cyanine7 is useful for detecting biotinylated antibodies. The excitation of APC/Cyanine7 by 600-635 nm laser light induces a fluorescence emission maximum of 780 nm.

Product Details

Verified Reactivity	Human, Mouse, Rat, All Species
Formulation	Phosphate-buffered solution, pH 7.2, containing 0.09% sodium azide.
Preparation	Streptavidin is conjugated with APC/Cyanine7 under optimal conditions.
Concentration	0.2 mg/ml (concentration relates to the Streptavidin only component of the conjugate)
Storage & Handling	The Streptavidin APC/Cyanine7 solution should be stored undiluted between 2°C and 8°C, and protected from prolonged exposure to light. Do not freeze.
Application	FC - Quality tested ICFC - Verified
Recommended Usage	Each lot of this Streptavidin APC/Cyanine7 is quality control tested by immunofluorescent staining with flow cytometric analysis. The concentration provided is based upon molecular mass of streptavidin independent of any additional molecular mass that might be added by the APC/Cyanine7 conjugation. For immunofluorescent staining, the recommended use of this reagent is =0.06 µg per 10 ⁶ cells in 100 µl staining volume. It is recommended that the reagent be titrated for optimal performance for each application.
Excitation Laser	Red Laser (633 nm)
Application Notes	Streptavidin-Allophycocyanin/Cyanine7 (APC/Cyanine7) is useful as a second step reagent for indirect immunofluorescent staining, when used in conjunction with biotinylated primary antibodies. The average molecular weight of Streptavidin-APC/Cyanine7 is 350 kD and Streptavidin alone is 52 kD.
Additional Product Notes	BioLegend is in the process of converting the name APC/Cy7 to APC/Cyanine7. The dye molecule remains the same, so you should expect the same quality and performance from our APC/Cyanine7 products. Please contact Technical Service if you have any questions.

Application References

(PubMed link indicates BioLegend citation)

- Maresz K, *et al.* 2005. *J. Neurochemistry* 95:437.
- Ponomarev ED, *et al.* 2006. *J. Immunol.* 176:1402. [PubMed](#).
- Ponomarev ED, *et al.* 2007. *J. Immunol.* 178:39.
- Mann MK, *et al.* 2007. *J. Immunol.* 178:3447. [PubMed](#)
- Ponomarev ED, *et al.* 2005. *J. Immunol Methods.* 300:32. [PubMed](#)
- Cao YA, *et al.* 2008. *Blood* [PubMed](#)
- Garidou L, *et al.* 2009. *J. Virol.* [PubMed](#)
- Dolgachev V, *et al.* 2009. *J. Immunol.* 183:5705. [PubMed](#)
- Sountoulidis A, *et al.* 2012. *PLoS One.* 7:e41460. [PubMed](#).
- Izumi T, *et al.* 2013. *Cytotherapy.* 15:481. [PubMed](#)
- Hamanaka S, *et al.* 2013. *Biochem Biophys Res Commun.* 435:586. [PubMed](#)
- Prince J, *et al.* 2013. *J. Immunol.* 191:4709. [PubMed](#)
- Phanse Y, *et al.* 2013. *Acta Biomater.* 9:8902. [PubMed](#)
- Orre M, *et al.* 2014. *Neurobiol Aging.* 35:1. [PubMed](#)
- Barbera M, *et al.* 2014. *Gut.* 64:11. [PubMed](#)
- Zhang Y, *et al.* 2014. *Infect Immun.* 82:1698. [PubMed](#)
- Peterson BC, *et al.* 2014. *J Leukoc Biol.* 95:809. [PubMed](#)
- Barbera M, *et al.* 2015. *Gut.* 64:11. [PubMed](#)
- Charmsaz S, *et al.* 2015. *PLoS One.* 10:130692. [PubMed](#)

Product Citations

- Kulkarni N, *et al.* 2017. *Eur J Appl Physiol.* 10.1007/s00421-017-3704-z. [PubMed](#)
- Luo H, *et al.* 2019. *Cell Rep.* 26:945. [PubMed](#)

3. Chen Z, *et al.* 2019. J Exp Med. 216:152. [PubMed](#)
4. Kimball A, *et al.* 2018. Arterioscler Thromb Vasc Biol. 38:1102. [PubMed](#)
5. Greenwald AC, *et al.* 2019. J Exp Med. 216:215. [PubMed](#)
6. Gudjonsson A, *et al.* 2019. Front Immunol. 10:1086. [PubMed](#)
7. Barman PK, *et al.* 2019. J Immunol. 202:2720. [PubMed](#)
8. Wang L, *et al.* 2019. Cell Rep. 29:1848. [PubMed](#)
9. Delacher M, *et al.* 2020. Immunity. 52:295. [PubMed](#)
10. Chen Z, *et al.* 2020. Cell Death Dis. 11:180. [PubMed](#)
11. Frodermann V, *et al.* 2019. Nat Med. 25:1761. [PubMed](#)
12. Ponomarev ED, *et al.* 2005. J Immunol Methods. 300:32:00. [PubMed](#)
13. Ponomarev E, *et al.* 2006. J Immunol. 176:1402. [PubMed](#)
14. Mann M, *et al.* 2007. J Immunol . 178:3447. [PubMed](#)
15. Cao Y, *et al.* 2008. Blood. 112:4494. [PubMed](#)
16. Dolgachev V, *et al.* 2009. J Immunol. 183:5705. [PubMed](#)
17. Garidou L, *et al.* 2009. J Virol. 83:8905. [PubMed](#)
18. Sountoulidis A, *et al.* 2012. PLoS One. 7:e41460. [PubMed](#)
19. Izumi T, *et al.* 2013. Cytotherapy. 15:481. [PubMed](#)
20. Hamanaka S, *et al.* 2013. Biochem Biophys Res Commun. 435:586. [PubMed](#)
21. Prince J, *et al.* 2013. J Immunol. 191:4709. [PubMed](#)
22. Phanse Y, *et al.* 2013. Acta Biomater. 9:8902. [PubMed](#)
23. Orre M, *et al.* 2014. Neurobiol Aging. 35:1. [PubMed](#)
24. Zhang Y, *et al.* 2014. Infect Immun . 82:1689. [PubMed](#)
25. Petersen B, *et al.* 2014. J Leukoc Biol. 95:809. [PubMed](#)
26. Barbera M, *et al.* 2015. Gut. 64:11. [PubMed](#)
27. Charmsaz S, *et al.* 2015. PLoS One. 10:130692. [PubMed](#)
28. Chen Y, *et al.* 2015. PLoS One. 10: 0135217. [PubMed](#)
29. Seri Y, *et al.* 2015. Sci Rep. 5: 13041. [PubMed](#)
30. Chao D, *et al.* 2015. PLoS One. 10: 0138107. [PubMed](#)
31. Giraddi R, *et al.* 2015. Nat Commun. 6: 8487. [PubMed](#)
32. Gillespie A, *et al.* 2016. PLoS One. 12: 1005419. [PubMed](#)
33. Lebert-Ghali C, *et al.* 2016. Blood. 127: 87-90. [PubMed](#)
34. Furusawa J, *et al.* 2016. PLoS Pathog. 12: 1005507. [PubMed](#)
35. Yeo S, *et al.* 2016. Cancer Res . 76: 3397 - 3410. [PubMed](#)
36. Shimizu T, *et al.* 2016. J Exp Med. 213: 1479 - 1496. [PubMed](#)
37. Lin K, *et al.* 2016. Sci Rep. 6:31444. [PubMed](#)
38. Marco Barros R, *et al.* 2016. Cell. 167: 203-218. [PubMed](#)
39. Sen D, *et al.* 2016. PLoS One. 11:e0165064. [PubMed](#)
40. Ritter M, *et al.* 2020. Ann Hematol. 99:2329. [PubMed](#)
41. Kimball AS, *et al.* 2020. Thromb Haemost. 120:289. [PubMed](#)

Antigen Details

Gene ID NA

Related Protocols

[Cell Surface Flow Cytometry Staining Protocol](#)

[Intracellular Flow Cytometry Staining Protocol](#)

For research use only. Not for diagnostic use. Not for resale. BioLegend will not be held responsible for patent infringement or other violations that may occur with the use of our products.

*These products may be covered by one or more Limited Use Label Licenses (see the BioLegend Catalog or our website, www.biolegend.com/ordering#license). BioLegend products may not be transferred to third parties, resold, modified for resale, or used to manufacture commercial products, reverse engineer functionally similar materials, or to provide a service to third parties without written approval of BioLegend. By use of these products you accept the terms and conditions of all applicable Limited Use Label Licenses. Unless otherwise indicated, these products are for research use only and are not intended for human or animal diagnostic, therapeutic or commercial use.

8999 BioLegend Way, San Diego, CA 92121 www.biolegend.com
Toll-Free Phone: 1-877-Bio-Legend (246-5343) Phone: (858) 768-5800 Fax: (877) 455-9587